Related references
Note: Only part of the references are listed.A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients
Margarita Garcia et al.
HUMAN GENE THERAPY (2019)
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Guillem Pascual-Pasto et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Liposome Encapsulation of Oncolytic Virus M1 To Reduce Immunogenicity and Immune Clearance in Vivo
Yalong Wang et al.
MOLECULAR PHARMACEUTICS (2019)
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
Adel Samson et al.
GUT (2018)
Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases
Ashlyn S. Everett et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2018)
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results
Vignesh T. Packiam et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Min Liang
CURRENT CANCER DRUG TARGETS (2018)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Untitled
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2018)
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
Ibrahim Ragab Eissa et al.
CANCERS (2018)
Measles virus: Background and oncolytic virotherapy
Sankhajit Bhattacharjee et al.
BIOCHEMISTRY AND BIOPHYSICS REPORTS (2018)
A novel oncolytic adenovirus based on simian adenovirus serotype 24
Tao Cheng et al.
ONCOTARGET (2017)
PUMA and NF-κB Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer
Chandini Thirukkumaran et al.
PLOS ONE (2017)
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Emma Eriksson et al.
CLINICAL CANCER RESEARCH (2017)
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Keri A. Streby et al.
CLINICAL CANCER RESEARCH (2017)
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J. J. Knox et al.
ANNALS OF ONCOLOGY (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Robert H. I. Andtbacka et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections
Haipeng Zhang et al.
HUMAN GENE THERAPY (2016)
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Stephanie Downs-Canner et al.
MOLECULAR THERAPY (2016)
Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01
Beatriz Vera et al.
PLOS ONE (2016)
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
Daxa M. Patel et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2016)
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
Tuuli Ranki et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The oncolytic virus, pelareorep, as a novel anticancer agent: a review
Romit Chakrabarty et al.
INVESTIGATIONAL NEW DRUGS (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ORCA-010, a Novel Potency-Enhanced Oncolytic Adenovirus, Exerts Strong Antitumor Activity in Preclinical Models
Wenliang Dong et al.
HUMAN GENE THERAPY (2014)
Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field
Dragomira Majhen et al.
HUMAN GENE THERAPY (2014)
Bioreducible polymers for therapeutic gene delivery
Young Sook Lee et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
Stephen J. Russell et al.
MAYO CLINIC PROCEEDINGS (2014)
Species D Human Adenovirus Type 9 Exhibits Better Virus-Spread Ability for Antitumor Efficacy among Alternative Serotypes
Junji Uchino et al.
PLOS ONE (2014)
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers
Yuan Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models
Shinichi Esaki et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors
Don G. Morris et al.
INVESTIGATIONAL NEW DRUGS (2013)
The oncolytic herpes simplex virus vector G47Δ effectively targets breast cancer stem cells
Weigen Zeng et al.
ONCOLOGY REPORTS (2013)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
Clinical Development of Oncolytic Viruses in China
Min Liang
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
Apoptin Enhances the Oncolytic Properties of Newcastle Disease Virus
Yantao Wu et al.
INTERVIROLOGY (2012)
Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond
Johanna K. Kaufmann et al.
TRENDS IN MOLECULAR MEDICINE (2012)
A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
A. Nakao et al.
CANCER GENE THERAPY (2011)
A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
Martijn P. Lolkema et al.
CLINICAL CANCER RESEARCH (2011)
Strategies to Enhance Viral Penetration of Solid Tumors
Elspeth Smith et al.
HUMAN GENE THERAPY (2011)
Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Specific Immune Response in Mice
Jad Maamary et al.
JOURNAL OF VIROLOGY (2011)
Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells
Mena Mansour et al.
JOURNAL OF VIROLOGY (2011)
Envelope-chimeric Entry-targeted Measles Virus Escapes Neutralization and Achieves Oncolysis
Tanner S. Miest et al.
MOLECULAR THERAPY (2011)
Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2010)
Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi et al.
CLINICAL CANCER RESEARCH (2010)
Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response
S. Rogee et al.
GENE THERAPY (2010)
Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer
Kyo Young Song et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2010)
The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin
Itay Lazar et al.
JOURNAL OF VIROLOGY (2010)
Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
Subbiah Elankumaran et al.
JOURNAL OF VIROLOGY (2010)
Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma
Gerd R. Silberhumer et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Curtis B. Thompson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma
Jennifer Altomonte et al.
MOLECULAR THERAPY (2010)
Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
Lynda Coughlan et al.
VIRUSES-BASEL (2010)
Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
J. Raty et al.
Current Molecular Pharmacology (2010)
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
T. Schulze et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model
Emily K. Mader et al.
CLINICAL CANCER RESEARCH (2009)
Genetically engineered Newcastle disease virus for malignant melanoma therapy
D. Zamarin et al.
GENE THERAPY (2009)
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
Holger Wilden et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer
Alan L. Parker et al.
JOURNAL OF VIROLOGY (2009)
Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses
Dmitriy Zamarin et al.
MOLECULAR THERAPY (2009)
Phase Ib Trial of Oncolytic Herpes Virus G207 shows safety of Multiple Injections and Documents Viral Replication
Manish K. Aghi et al.
MOLECULAR THERAPY (2009)
Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre- and Post-tumor Resection for Recurrent GBM
James M. Markert et al.
MOLECULAR THERAPY (2009)
Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
M. M. Zulkifli et al.
NEUROLOGICAL RESEARCH (2009)
Bioselection of a Gain of Function Mutation that Enhances Adenovirus 5 Release and Improves Its Antitumoral Potency
Alena Gros et al.
CANCER RESEARCH (2008)
Adenovirus serotype 5 hexon mediates liver gene transfer
Simon N. Waddington et al.
CELL (2008)
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Laura Vidal et al.
CLINICAL CANCER RESEARCH (2008)
Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes
F. Puehler et al.
GENE THERAPY (2008)
Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10
Daisuke Watanabe et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2008)
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
Peter Forsyth et al.
MOLECULAR THERAPY (2008)
Crystal structure of measles virus hemagglutinin provides insight into effective vaccines
Takao Hashiguchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus
Adam Vigil et al.
CANCER RESEARCH (2007)
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
Peter Abbink et al.
JOURNAL OF VIROLOGY (2007)
Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus
Yoko Ushijima et al.
MICROBES AND INFECTION (2007)
History of oncolytic viruses: Genesis to genetic engineering
Elizabeth Kelly et al.
MOLECULAR THERAPY (2007)
Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma
Yasushi Fujimoto et al.
ACTA OTO-LARYNGOLOGICA (2006)
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines
Sateesh Krishnamurthy et al.
JOURNAL OF VIROLOGY (2006)
Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Δγ134.5 mutants of herpes simplex virus 1
KD Smith et al.
JOURNAL OF VIROLOGY (2006)
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer
N Ramesh et al.
CLINICAL CANCER RESEARCH (2006)
Recent progress in the battle between oncolytic viruses and tumours
KA Parato et al.
NATURE REVIEWS CANCER (2005)
Oncolytic herpes simplex virus vector G47Δ in combination with androgen ablation for the treatment of human prostate adenocarcinoma
H Fukuhara et al.
CLINICAL CANCER RESEARCH (2005)
Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation
JW Schoggins et al.
JOURNAL OF VIROLOGY (2005)
Coexpression of UL20p and gK inhibits cell-cell fusion mediated by herpes simplex virus glycoproteins gD, gH-gL, and wild-type gB or an endocytosis-defective gB mutant and downmodulates their cell surface expression
E Avitabile et al.
JOURNAL OF VIROLOGY (2004)
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia
CM Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Herpes simplex virus glycoprotein K, but not its syncytial allele, inhibits cell-cell fusion mediated by the four fusogenic glycoproteins, gD, gB, gH, and gL
E Avitabile et al.
JOURNAL OF VIROLOGY (2003)
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway
J Fueyo et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet
W Liang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors
VW van Beusechem et al.
GENE THERAPY (2003)
Genetic retargeting of adenovirus: Novel strategy employing deknobbing of the fiber
MK Magnusson et al.
JOURNAL OF VIROLOGY (2001)
Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1
F Farassati et al.
NATURE CELL BIOLOGY (2001)
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
FR Khuri et al.
NATURE MEDICINE (2000)
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
I Dmitriev et al.
JOURNAL OF VIROLOGY (2000)
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
JM Markert et al.
GENE THERAPY (2000)
Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells
CC Termeer et al.
CANCER GENE THERAPY (2000)
Share Paper
